We compared the angiographic and long-term clinical outcomes of patients with and without overlap of drugeluting stents (DES).
Stent overlap has been reported in as many as 30% of patients undergoing percutaneous coronary interventions owing to excessive lesion length, edge dissections, or incomplete stent coverage (1) (2) (3) . Clinical outcome of patients with overlapping bare-metal stents (BMS) has been found to be inferior to that of patients treated with a single BMS, largely related to increased rates of target lesion revascularization (TLR) (4 -7) . The potent suppression of neointimal hyperplasia afforded by first-generation drug-eluting stents (DES) with a reduction in clinical and angiographic restenosis raised hopes of further improvement of results in patients with stent overlap (8 -12 ). Yet, clinical outcomes of overlapping DES demonstrated conflicting results. A pooled analysis of studies assessing clinical outcomes of overlapping sirolimus-eluting stents (SES) showed similar rates of ischemic end points and repeat revascularization at both 30 days and 8 months compared with a single SES, and a significant reduction in the need for repeat revascu-larization compared with a BMS (13) . Conversely, multiple overlapping paclitaxel-eluting stents (PES) were associated with improved efficacy but increased rates of periprocedural myonecrosis compared with overlapping BMS, presumably related to more frequent side branch compromise (14, 15) .
More recently, safety concerns surfaced with the use of first-generation DES during long-term follow-up, presumably related to delayed healing and impaired endothelialization (16) . The latter phenomenon may be particularly pronounced at sites of DES overlap owing to increased drug and polymer concentrations. One experimental study specifically addressed the differential response of arterial healing at sites of DES overlap. Compared with nonoverlapping DES and BMS sites, overlapping DES segments showed more neutrophils, eosinophils, and fibrin deposition, suggesting impaired healing and increased inflammation (17) . However, the impact of these findings on long-term clinical outcomes is not well established. The objective of the present study was to compare the angiographic and longterm clinical outcomes of patients with overlapping DES compared with those of patients with multiple DES with no overlap, or a single DES implanted in a vessel.
Methods
Patient population and intervention. The design of the SIRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization) trial was previously reported (18) . It was an observer-blind, randomized, controlled trial comparing the safety and efficacy of SES and PES in 1,012 patients undergoing percutaneous coronary interventions. Eligible patients had a history of stable angina or acute coronary syndrome and presented with at least 1 lesion with a stenosis Ն50% in a vessel with a reference vessel diameter between 2.25 and 4.0 mm suitable for stent implantation. There were no limitations on the number of treated lesions and vessels or lesion length. Before or at the time of the procedure, patients received at least 100 mg of aspirin, a loading dose of clopidogrel, and unfractionated heparin (70 to 100 U/kg body weight). After the procedure, all patients were prescribed lifelong aspirin therapy and clopidogrel for 12 months. All patients were requested at the time of randomization to undergo repeat angiography at 8 months. Subsequently, a research nurse contacted all patients and asked them at least once to schedule an appointment for repeat angiography. The study complied with the Declaration of Helsinki regarding investigations in humans and was approved by the research ethics committees at the University Hospitals of Bern and Zurich, Switzerland. All patients provided written informed consent. Definition and end points. Stent overlap was defined as the presence of Ն2 stents within a single treated lesion and an overlapping stent zone of at least 1 mm, as determined by quantitative coronary angiography. Overlapping stent zones were identified based on the position of the stent balloon markers of the second stent relative to the first stent. Adverse events were assessed during the hospitalization, at 1, 6, and 9 months and at 1, 2, and 3 years. An independent clinical events committee unaware of the patient's treatment assignment adjudicated all end points. The prespecified primary end point was a composite of major adverse cardiac events (MACE), defined as cardiac death, myocardial infarction (MI), or ischemiadriven TLR at 9 months. Secondary end points included ischemia-driven TLR, target vessel revascularization, or target vessel failure at all scheduled follow-up visits. Definitions of ischemia-driven TLR, MI, and stent thrombosis were published previously (18) . Quantitative coronary angiography. Coronary angiograms were digitally recorded at baseline, immediately after stent implantation, and at follow-up and were assessed at the angiographic core laboratory of the University of Bern. Digital angiograms were analyzed with the use of an automated edge-detection system (CAAS II, Pie Medical Imaging, Maastricht, the Netherlands). Quantitative measurements included the reference vessel diameter, the minimal lumen diameter, and percentage of diameter stenosis. Binary restenosis was defined as stenosis Ն50% in the target lesion at angiographic follow-up. All angiographic measurements of the target lesion were obtained within the stent and the areas 5 mm proximal and distal to the stent edge. All lesions of patients with stent overlap who underwent TLR at any time point up to 3 years were analyzed by quantitative coronary angiography to determine the zone of restenosis triggering the repeat revascularization and the site of minimal lumen diameter. The restenosis pattern was analyzed independently by 2 fellows in cardiology (L.R. and L.L.). In cases of disagreement, an external cardiologist who was not involved in the SIRTAX trial made the final decision. Statistical analysis. For the purpose of the present study, we performed an analysis of clinical and angiographic outcomes stratified according to the presence or absence of stent overlap. Among patients without overlap, we specified 2 groups: the first group consisted of patients with multiple DES within a vessel but no overlap, and the second group consisted of the remaining patients who had a single DES implanted within a vessel.
Patient characteristics at baseline were compared among the 3 patient groups using chi-square tests for binary and maximum-likelihood linear regression models for continuous outcomes, which allowed the comparison of the 3 groups. In cases of multiple lesions in a patient, we restricted the analysis to the lesions that led to the final classification lesions. There were significant differences among groups in age, the presence of multivessel disease, and the number of lesions per patient (all p values Ͻ0.01) ( Table 1) . Lesion characteristics differed significantly among groups in all respects except reference vessel diameter (Table 2) ; lesions with stent overlap were most complex. Procedural results are summarized in Table 3 . Patients with DES overlap received more and longer stents per lesion compared with the control groups (p Ͻ 0.01) and differed in acute gain (p Ͻ 0.01). The reasons for stent overlap were, in descending order (Table 4) , excessive lesion length in relation to maximal available stent length (43.5%), incomplete target lesion coverage (35.5%), and dissections at the stent edges (19.6%). Clinical outcomes. Clinical outcome data were complete for 1,002 (99.0%) of 1,012 patients at 3 years of follow-up.
Crude and adjusted analyses of clinical events at 3 years of follow-up are presented in Table 5 . Compared with controls, patients with DES overlap were more likely to experience a MACE in crude (p Ͻ 0.01) and adjusted (p ϭ 0.04) analyses. The individual hazard ratio comparing DES overlap patients with patients with multiple DES in a Conversely, the hazard ratio comparing DES overlap patients with patients with a single DES in a vessel was 1.93 in crude analyses (95% CI: 1.3 to 2.85, p ϭ 0.01) and 1.50 in adjusted analyses (95% CI: 0.91 to 2.46, p ϭ 0.11). The differences were driven by both effectiveness (crude and adjusted analyses of TLR: p Ͻ 0.01 and p Ͻ 0.10, respectively) and safety end points (composite of death or MI: p ϭ 0.01 and p ϭ 0.02, respectively). Table 6 presents shorter-term results at 30 days of follow-up; no clear-cut pattern could be detected. There was little evidence of a worse outcome in patients with stent overlap, but 95% CIs were wide. At 9 months, the pattern of MACE, TLR, and the composite of death or MI was similar to that at 3 years. In adjusted analyses, the hazard ratio comparing DES overlap patients with patients with Ͼ1 stent per vessel but Values are n (%) or mean Ϯ SD. *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without overlap. ‡Patients with a single stent in a vessel. §p values are for differences among groups from linear and logistic regression models using robust sirolimus-eluting stents that accounted for the correlation of characteristics of lesions within patients. ACC/AHA ϭ American College of Cardiology/American Heart Association. Values are mean Ϯ SD. *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without overlap. ‡Patients with a single stent in a vessel. §p values are for differences among groups from linear and logistic regression models using robust sirolimus-eluting stents that accounted for the correlation of characteristics of lesions within patients. Figure 2 presents the distribution of restenoses across the different zones of the treated lesions. Of 25 lesions, 17 (68%) had documented binary restenosis at the zone of stent overlap as opposed to 6 (24%) at the proximal stent zones without overlap, 4
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(16%) at the distal stent zones without overlap, 4 (16%) within the proximal edge, and 1 (4%) within the distal edge (p for trend Ͻ0.01). The minimal lumen diameter within a treated lesion, corresponding to the area of maximal restenosis, was located at the zone of DES overlap in 17 of the 25 (68%) lesions, within the proximal or distal stent area in 4 (16%) lesions, and within 5 mm of the proximal or distal stent edges in another 4 (16%) lesions (p for trend Ͻ0.01).
In 18 lesions, restenoses were classified as focal (72%), as multifocal in 3 (12.0%), and as diffuse in the remaining 4 (16.0%). Among lesions classified as having a focal restenosis, 6 had total occlusion. Focal restenoses predominantly occurred in the overlapping stent zone; 3 (50%) of 6 cases with total occlusion and 9 (75%) of 12 cases without total occlusion were found at the zone of stent overlap. Figure 3 shows a representative example of focal restenosis associated with stent overlap, and Figure 4 shows an example of a lesion with stent overlap and subsequent total occlusion.
Discussion
In this analysis of the 3 years of follow-up of the SIRTAX trial, we found patients with DES overlap at increased risk of MACE, including repeat revascularization and ischemic adverse events. At 1 month, there was little evidence of increased rates of MACE associated with DES overlap, but 95% CIs were wide and we cannot exclude substantial differences among groups. Clinical findings at 9 months and 3 years of worse outcomes in patients with overlap were echoed by inferior angiographic outcomes at 8 months.
Twenty-five patients with DES overlap and available angiographic data underwent TLR of a lesion. Among these, 12 (48%) had focal restenosis or total occlusion at the site of overlap and an additional 5 (20%) had diffuse restenosis with the minimal lumen diameter located at the site of overlap. The most frequent reasons for DES overlap were an excessive lesion length in relation to maximal available stent length and insufficient lesion coverage, whereas peristent or guiding catheter dissections were rare. Study strengths and limitations. Our analysis is based on the nearly complete follow-up of the SIRTAX trial, a randomized superiority trial in an unselected all-comer population seen at 2 major cardiovascular centers in Switzerland. Allocation of patients was concealed, treatment protocols were standardized, there was active follow-up of patients with blinded adjudication of clinical events, and the analysis was according to the intention-to-treat principle (18) . A major limitation of this and any other study comparing outcomes in patients with and without overlap is the selection of control individuals, which is inherently related to prognosis. Patients with stent overlap tend to have more, longer, and more complex lesions than controls, and statistical attempts to control the resulting confounding may only be partially successful. We therefore opted for comparing patients with stent overlap with 2 different groups: 1 group of patients with multiple DES within a vessel but no Values are n (%). *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without overlap. ‡Patients with a single stent in a vessel. §Adjusted for diabetes, lesion length, reference vessel diameter, number of lesions, stent allocation, lesion classification, and the presence of acute coronary syndrome. ʈp values for differences in hazards among groups in crude and adjusted analyses. Italics indicate pairwise comparisons that are statistically significant at the conventional 2-sided p Յ 0.05 and corresponding 95% confidence intervals not overlapping the line of no difference at 1. CI ϭ confidence interval; HR ϭ hazard ratio; MACE ϭ major adverse cardiac events; MI ϭ myocardial infarction; TLR ϭ target lesion revascularization.
overlap and 1 group with implantation of a single DES only within a vessel. To ensure full transparency, we present results from both unadjusted analyses and analyses adjusted for the most important confounding factors. It is the consistency of the different comparisons and of the crude and adjusted analyses that supports our conclusion that patients with DES overlap are at increased risk of MACE Clinical Events at 30 Days Table 6 Clinical Events at 30 Days Values are n (%). *Patients with multiple drug-eluting stents in a vessel with overlap. †Patients with multiple stents in a vessel without overlap. ‡Patients with a single stent in a vessel. §Adjusted for diabetes, lesion length, reference vessel diameter, number of lesions, stent allocation, lesion classification, and presence of acute coronary syndrome. ʈp values for differences in hazards among groups in crude and adjusted analyses.
N/A ϭ not available; other abbreviations as in Table 5 .
Figure 1 Time to Event Curves for Various Clinical End Points
Kaplan-Meier cumulative event curves for major adverse cardiac events (MACE) (A) (composite of cardiac death, myocardial infarction [MI], or ischemia-driven revascularization of the target lesion), target lesion revascularization (TLR) (B), and the composite of overall death or MI (C). p values are for differences in hazards among groups in crude and adjusted analyses. DES ϭ drug-eluting stent(s). (Fig. 1) , it becomes obvious that differences become more pronounced after termination of the follow-up at 1-year. Our findings are biologically plausible. Analysis of the pattern of restenosis in patients with DES overlap who underwent TLR during the follow-up period revealed that the maximal lumen narrowing occurred at sites of DES overlap in the majority of patients, which in turn suggests a causal link between overlap and risk of restenosis. We can only speculate as to the mechanism of the increased risk of death or MI found in our study. Experimental studies raised concerns regarding both the safety and efficacy of overlapping DES because of the increased density of polymer, drug, and stent material. Decreasing efficacy of overlapping PES has been observed, for example, with increasing follow-up time in a porcine coronary artery model (25) . Finn et al. (17) reported signs of incomplete and delayed endothelialization, greater accumulated fibrin deposition as markers of delayed healing, and increased inflammation at sites of overlapping DES in rabbit iliac arteries. Incomplete endothelialization and increased inflammation at sites of overlapping DES have also been found in a porcine restenosis model (26) . Our findings are also corroborated by a recent cohort study in patients who had undergone DES implantation. During a mean follow-up period of 399 days, Alfonso et al. (27) reported a coronary artery aneurysm rate of 1.3% after DES implantation. In 4 of 15 patients with a documented aneurysm, the aneurysm was found at the zone of stent overlap, which suggests excessive vessel remodeling as a result of the high density of drug or polymer. Another recent clinical investigation with angioscopy demonstrated incomplete neointimal coverage after SES, but not BMS, implantation at 2 years of follow-up. This phenomenon was particularly pronounced in 4 patients with DES overlap (28) . Using optical coherence tomography 6 months after SES implantation, Matsumoto et al. (29) observed incomplete stent strut coverage in the majority of patients (84%) and overlapping SES showed a higher rate of strut malapposition than nonoverlapping SES (8% vs. 0.8%, respectively; p Ͻ 0.0001). Although the findings from these imaging studies were not associated with adverse clinical outcomes, they may contribute to ischemic adverse events during longer term follow-up, particularly after dual antiplatelet therapy was terminated. Although we observed similar rates of stent thrombosis among DES with and without overlap in the present study, much larger patient populations would be required to statistically establish differences between both groups.
Angiographic Results
Conclusions
DES overlap occurs in a considerable proportion of patients undergoing percutaneous coronary intervention in routine clinical practice. The most common reasons for DES overlap are excessive lesion length and incomplete lesion coverage. DES overlap does not seem to be associated with an increased risk of periprocedural MI, but is associated with impaired clinical and angiographic outcomes during long-term follow-up.
